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Dipyridamole inhibits TGF-–induced collagen gene expres- Peritoneal fibrosis (PF) is one of the most serious
sion in human peritoneal mesothelial cells. complications after long-term continuous ambulatory
Background. Peritoneal matrix accumulation is characteris- peritoneal dialysis (CAPD) [1]. In vitro and in vivo studiestic of peritoneal fibrosis (PF). Continuous ambulatory perito-
have shown that proliferation of human peritoneal meso-neal dialysis (CAPD) patients who had persistent transforming
thelial cells (HPMCs) accompanied by matrix expansiongrowth factor- (TGF-) in their drained effluent had an in-
creased risk of PF. We previously reported that TGF- stimu- is important in the pathogenic process of PF [2]. Trans-
lates the expression of types I and III collagen mRNA in cultured forming growth factor- (TGF-) increases matrix accu-
human peritoneal mesangial cells (HPMCs), which may predis- mulation and has been regarded as the central mediatorpose them to develop PF. Pharmacological interventions to
of the fibrosing process in clinical diseases. CAPD pa-attenuate TGF-–stimulated matrix accumulation in HPMC
tients who had persistent TGF- in their drained effluentmay have therapeutic potential for the treatment of PF. The
SMAD family and the extracellular signal-regulated protein also had an increased risk of PF [3]. In addition, we
kinase (ERK1/2, p44/p42) pathways have been shown to partic- previously reported that TGF- stimulates expression of
ipate in TGF- signaling. Our current study identified these
types I and III collagen mRNA in cultured HPMCs [4].signal pathways in HPMCs and investigated the molecular
These observations support the hypothesis that TGF-mechanisms involved in the inhibitory effects of dipyridamole
on TGF-–induced collagen gene expression in HPMCs. may contribute to the development of PF. Pharmacologi-
Methods. HPMCs were cultured from human omentum by cal interventions that can attenuate TGF-–stimulated
an enzyme digestion method. Expression of collagen 1(I) matrix accumulation in HPMCs have a therapeutic po-
mRNA was determined by Northern blotting. The SMAD pro-
tential for the prevention or retardation of PF.teins and the ERK1/2 activity were determined by Western
Despite the well-known association between TGF-blotting.
Results. TGF--stimulated collagen 1(I) mRNA expres- and matrix accumulation, little information is available
sion of HPMC was inhibited by dipyridamole in a dose-depen- regarding the cellular signals TGF- uses to induce this
dent manner. Smad2 and ERK1/2 were activated in response process. On the cell membrane, TGF- binds to the type
to TGF-; however, TGF- had little effect on the protein
II receptor, which recruits the type I receptor into aexpression of Smad4. The addition of PD98059, which blocked
complex [5]. The type I receptor, once phosphorylatedactivation of ERK1/2, suppressed TGF-–induced collagen
1(I) mRNA expression in a dose-dependent manner. At a by the type II receptor, activates Smad2 and allows it to
concentration that inhibited collagen gene expression (17 g/ form a heteromultimer with Smad4. This complex then
mL), dipyridamole suppressed ERK1/2 activation by TGF-. is translocated to the nucleus to regulate transcription
In contrast, the same concentration of dipyridamole had no
of target genes. In a study of human mesangial cells,effect on TGF-–induced activation of Smad2.
Poncelet, de Caestecker and Schnaper demonstratedConclusion. Dipyridamole inhibits TGF-–induced colla-
gen gene expression in HPMC through modulation of the ERK that SMAD proteins are activated by TGF-1 and then
pathway. Our study of dipyridamole may provide therapeutic participate in TGF-1–stimulated type I collagen expres-
basis for clinical applications in the prevention of PF. sion [6]. In addition to the SMAD proteins, the mitogen-
activated protein kinase (MAPK) pathways have been
proposed to function downstream of the TGF- signalingKey words: ERK pathway, cell signaling, signal transduction, fibrosis,
peritoneal fibrosis, transforming growth factor-. pathways [5, 7]. The MAPK pathways actually contain
three phosphorylation cascades: the extracellular signal-Received for publication September 11, 2000
regulated protein kinase (ERK), the c-Jun N-terminaland in revised form April 30, 2001
Accepted for publication May 2, 2001 kinase (JNK), and the p38HOG MAPK. Recently, in a study
of human mesangial cells, Hayshida et al demonstrated 2001 by the International Society of Nephrology
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that ERK are activated by TGF-, and the blockade of for cAMP were obtained from Cayman Chemical (Ann
Arbor, MI, USA). Selective cAMP-dependent protein ki-the ERK pathway results in inhibition of TGF-–
induced type I collagen gene expression [8]. These re- nase (PKA) inhibitor H-89 was obtained from Calbiochem
(La Jolla, CA, USA). BCA reagents were from Pierceports suggest that both the SMAD and ERK pathways
may be involved in TGF-–induced collagen synthesis (Rockford, IL, USA). Phosphorylated and nonphosphory-
lated polyclonal antibodies to ERK1/2, Smad2, and Smad4and fibrogenesis. However, there are, to our knowledge,
no data available regarding the presence and activation were all purchased from Biolabs (New England, MA,
USA). Human collagen 1 (I) cDNA was purchased fromof these intracellular signals of TGF- in HPMCs.
Dipyridamole [2,6-bis(diethanolamino)-4,8-dipiperi- American Type Culture Collection (Rockville, MD, USA).
Agents used to isolate the total RNA and Northern blotdinopyrimido-(5,4-d)-yrimidine] is a widely used anti-
platelet agent and acts as an phosphodiesterase inhibitor analysis were obtained from Boehringer Mannheim
(Mannheim, Germany) unless otherwise specified. Di-that increases intracellular cAMP [9]. In addition to its
antiplatelet effect, we previously demonstrated that di- pyridamole used in this study was a generous gift from
Boehringer Ingelheim. All other chemicals used were ofpyridamole in rat mesangial cells may exert an antifibro-
genic effect by reducing the expression of type I collagen analytical grade.
mRNA [10]. It has been shown in rat aortic smooth
Establishment of HPMC culturemuscle cells (SMC) [11] and mesangial cells [12] that
raising intracellular cAMP inhibits activation of ERK. Specimens of human omentum were obtained from
abdominal surgical procedures for elective gastric cancerOur previous reports of HPMC using agents that in-
creased intracellular cAMP also demonstrated a reduced resection and the omentum was grossly normal. HPMC
culture was carried out as in our previous reports [4, 13].expression of collagen 1(I) mRNA [4, 13]. These data
support our hypothesis that dipyridamole may attenuate Briefly, the surgically removed human omentum was
washed three times with phosphate-buffered saline (PBS)TGF-–induced collagen synthesis in HPMCs. We spec-
ulated that, by increasing intracellular cAMP, dipyri- and then digested with trypsin EDTA (0.125%; GIBCO)
for 15 minutes. After centrifugation, the cell pellet wasdamole has an inhibitory effect on TGF-–induced acti-
vation of SMAD proteins and/or the ERK pathways. washed with culture medium and then seeded into a gela-
tin-coated (1 mg/mL) flask. The medium was changed onWe report here an antifibrogenic effect of dipyridam-
ole on TGF-–treated HPMCs. The intracellular down- the third day. RPMI-1640 medium containing 20% FCS,
penicillin (100 U/mL), streptomycin (100 g/mL), andstream factors, including SMAD proteins and ERK path-
ways, are explored in TGF-–stimulated HPMCs. The insulin (30 g/mL) was used. After two to four days,
the cells became confluent and were subcultured withregulatory effects of dipyridamole on these intracellular
signals of HPMCs and the resulting inhibition of collagen medium containing 10% FCS. HPMCs were identified
by the presence of vimentin and cytokeratin, but withoutgene expression also were investigated. Our results may
provide a pharmacological basis for using dipyridamole desmin and factor VIII-related antigen by the immuno-
fluorescence method. All experiments were performedin the treatment of PF.
in passage 1 to 3 cells.
METHODS Northern blot analysis
Materials To determine the effect of dipyridamole on collagen
gene expression, HPMCs were grown in RPMI supple-Fetal calf serum (FCS) was obtained from Biochrome
KG (Berlin, Germany). Culture flasks and plates were mented with 10% FCS until subconfluency. HPMCs were
arrested by 0.5% FCS for 24 hours and were then treatedpurchased from Corning (Corning, NY, USA) and pre-
coated with 1.6 g/cm2 of Vitrogen 100 (Celtrix Lab, with TGF- (2.5 ng/mL) in the absence or presence of
various concentrations of dipyridamole. After 24 hours,Palo Alto, CA, USA) before cell loading. Trypsin-ethyl-
enediaminetetraacetic acid (EDTA), RPMI-1640 me- cells were harvested for isolation of total RNA, as pre-
viously described [4, 13]. The concentration of each sam-dium, glutamine, and trypan blue were obtained from
GIBCO (Grand Island, NY, USA). Aprotinin, adeno- ple was determined using spectrophotometry with the
absorbance at 260 nm (A260). The purity of each samplesine 5-triphosphate (ATP), leupeptin, phenylmethylsul-
fonyl fluoride (PMSF), sodium orthovanadate (Na3VO4), was determined based on the ratio of A260 to A280. Ten
micrograms of RNA were electrophoresed on a 1% aga-bovine serum albumin (BSA), 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT), dibutyryl- rose gel containing 1 mol/L formaldehyde in MOPS
buffer (0.2 mol/L morpholinopropanesulfonic acid, 0.05cAMP (DBcAMP), 3-isobutyl-1-methylxanthine (IBMX),
and other tissue culture reagents were purchased from mol/L Na acetate, 0.01 mol/L EDTA). Equivalency of
sample loading and lack of degradation was verified bySigma (St. Louis, MO, USA). TGF-1 was obtained from
R&D Laboratory. The enzyme immunoassay (EIA) kits ethidium bromide staining of 28S and 18S rRNA bands.
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Then RNA was transferred to nylon membranes by over- Statistical analysis
night capillary action followed by fixation in an ultravio- The results are expressed as mean  SEM, unless
let cross-linker. otherwise stated. These statistical analyses were carried
For Northern blotting, a 1.5 kb EcoRI fragment of out using StatView IV on a personal computer. Statistical
collagen 1(I) and a 0.7 kb HindIII/EcoRI fragment significance (P  0.05) was evaluated using the Student
of collagen 1(III) were subcloned, respectively, into t test or one-way analysis of variance with modified t test
pBSII/SK (Stratagene, La Jolla, CA, USA) and used as performed using the Bonferroni correction.
templates for in vitro transcription of antisense digoxi-
genin-conjugated riboprobes according to the manufac-
RESULTSturer’s instructions (Boehringer Mannheim). The blots
Dipyridamole inhibits TGF-–induced 1(I) andwere developed using CSPD (Boehringer Mannheim) as
1(III) mRNA expression in HPMCsthe substrate for alkaline phosphatase, as described by
the supplier. The signal intensity recorded on x-ray film The effects of TGF- and dipyridamole on the expres-
was then quantified with computerized densitometry and sion of collagen 1(I) and 1(III) mRNA level were
was normalized against the signal of glyceraldehyde-3- analyzed in HPMC. Similar to our previous report [4],
phosphate dehydrogenase (GAPDH) messages. Figure 1 shows that TGF- induced collagen 1(I) and
1(III) mRNA expression in HPMCs. Compared with
Cell preparations and protein extraction basal level (control), TGF- resulted in a 5.2-fold incre-
Human peritoneal mesothelial cells were grown in 10 ment of collagen 1(I) mRNA expression. A dose-depen-
cm dishes until subconfluency, growth-arrested for 24 dent reduction of collagen 1(I) mRNA expression by
hours with medium containing 0.5% FCS, and then har- dipyridamole was then determined. As illustrated in Fig-
vested after treatment at the indicated time points with ure 1A, a significant reduction of TGF-–induced colla-
200 L ice-cold lysis buffer (50 mmol/L Tris-HCl, pH7.5, gen 1(I) mRNA occurred with 17 g/mL dipyridamole.
150 mmol/L NaCl, 10% glycerol, 1% Triton X-100, 2 Dipyridamole had been reported to exert its biological
mmol/L EDTA, 2 mmol/L EGTA, 40 mmol/L -glycero- effect through the cAMP-PKA pathway [9]. Accordingly,
phosphate, 50 mmol/L NaF, 10 mmol/L sodium pyro- we examined effect of DBcAMP on TGF-–induced col-
phosphate, 200 mol/L sodium orthovanadate, 10 g leu- lagen 1(I) and 1(III) mRNA expression, and tested
peptin/mL, 200 units of aprotinin/mL, 1mol/L pepstatin whether the blockade of cAMP-PKA pathway could over-
A, 1 mmol/L PMSF, 100 mmol/L okadaic acid). The cell come the inhibitory effect of dipyridamole in TGF-–
lysate was centrifugated at 14,000 rpm for 10 minutes, treated HPMC. As expected, the addition of DBcAMP
and the protein concentration of the supernatant was (1 mmol/L), a membrane-permeable analogue of cAMP,
measured by BCA protein assay (Pierce). decreased the expression of collagen 1(I) and 1(III)
mRNA expression. Moreover, in the presence of H-89,
Western blot analysis a nonspecific PKA inhibitor, the inhibitory effects of
Western blotting analyses of ERK1/2 and Smad2 phos- dipyridamole on collagen 1(I) and 1(III) mRNA ex-
phorylation were performed according to the manufac- pression were almost completely reversed.
turer’s protocol using phospho-specific antibodies. Briefly,
SMAD proteins are present in HPMC and the Smad2HPMCs were low serum (0.5% FCS) starved for 24 hours
is activated by TGF-and then stimulated with TGF- (2.5 ng/mL) for differ-
ent lengths of time. To evaluate the inhibitory effect of To investigate the molecular mechanisms involved in
dipyridamole on TGF-–stimulated activation of ERK TGF-–induced collagen gene expression in HPMCs, we
and/or SMAD pathways, HPMC was incubated with 17 first examined whether HPMCs express SMAD proteins
g/mL dipyridamole for 30 minutes before stimulation and then determined their modulations by TGF- (Fig.
with TGF-. Cells were harvested at the indicated time 2). Protein levels of Smad2 (58 kD) were detected in
period for Western blotting. In addition, lanes of cells quiescent (control) HPMC; they slightly increased from
were treated with 3 or 10 mol/L H89 for 30 minutes 15 minutes to 4 hours, and then decreased by 16 hours
before dipyridamole. Cell lysates (20 g protein) were of incubation with TGF- (Fig. 2A). Protein levels of
separated by SDS-PAGE (12%) and then transferred to Smad4 (62 kD) did not change in response to TGF-.
PVDF membrane (Millipore, Bedford, MA, USA). For These data are similar to those observed in other cells,
immunodetection, membranes were probed with primary demonstrating that SMAD proteins are also present in
antibody followed by incubation with peroxidase-conju- HPMCs.
gated secondary antibodies. Bands were visualized by To investigate whether TGF- activates Smad2 in
the enhanced chemiluminescence (ECL) system (Amer- HPMC, lysates were electrophoresed through two paral-
lel polyacrylamide gels, followed by Western blotting.sham).
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Fig. 1. Effects of dipyridamole on collagen
1(I) and 1(III) mRNA levels. All human
peritoneal mesothelial cells (HPMCs) were
grown as described in the Methods section.
Some cells were preincubated with dipyridam-
ole (DP), DBcAMP (1 mmol/L), or H-89 (10
mol/L). After these additions, the cells were
then incubated with TGF- (2.5 ng/mL) for
24 hours in the presence of the same additions.
(A) Representative Northern blots of collagen
1(I) mRNA are shown in the top panel. Den-
sitometric analysis of blots from four separate
experiments is shown in the bottom panel.
Values in the graph are shown as fold increase
over control. *P  0.05 vs. TGF- alone (lane
3). (B) Northern blots demonstrating inhibi-
tory effect of dipyridamole on TGF-–induced
collagen 1(III) mRNA expression.
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Fig. 2. Expression of SMAD proteins in
HPMCs. HPMCs were treated with TGF-
(2.5 ng/mL) for the indicated time periods,
and then harvested for Western blotting. (A)
Representative blots from three separate ex-
periments of Smad2 and Smad4 protein ex-
pressions are shown. (B) Time course of acti-
vation of Smad2 by TGF-. HPMCs were
treated as described. Shown at the top are
representative blots developed with anti-phos-
pho-Smad2 antibody for analysis of Smad2 acti-
vation or with nonphospho-Smad2 antibody for
protein levels. Results of densitometric analy-
sis, expressed as a ratio between phospho-
and nonphospho-Smad2, from four separate
experiments are shown at the bottom. *P 
0.05, relative to control.
As shown in Figure 2B, TGF- (2.5 ng/mL) induced a Activation of the ERK pathway by TGF- in HPMCs
rapid phosphorylation of Smad2 that began within 15 In previous (unpublished) studies we found that ERK1
minutes, peaked at 15 to 30 minutes, and then returned and ERK2 were present in primary culture of HPMC
to baseline values by 8 hours. Results are expressed as the and were activated after treatment with platelet-derived
ratio between phosphorylated and nonphosphorylated growth factor (PDGF; 20 ng/mL). We also found that this
PDGF-induced ERK1/2 activation could be completelySmad2.
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Fig. 3. Time course of activation of ERK1/2 by TGF-. HPMCs were Fig. 4. Effect of PD98059 on TGF- induced collagen 1(I) mRNA
treated as described in Figure 2. Representative blots developed with expression. HPMCs were treated with various concentrations of
anti-phospho-ERK1/2 antibody (top) or non-phospho-ERK1/2 anti- PD98059 for one hour and then incubated with TGF- for 24 hours.
body (middle) are shown. Results of densitometric analysis, expressed as 1(I) mRNA expression was assessed as described in Figure 1. Repre-
a ratio between phospho- and nonphospho-ERK1/2, from four isolated sentative Northern blots are shown at the top. Results of densitometric
experiments, are shown in the bottom panel. *P  0.05, relative to analysis from four isolated experiments are shown in the bottom panel.
control. Values in the graph are shown as fold increase over control. *P  0.05
vs. TGF- alone (lane 3).
inhibited by preincubation with PD98059, a specific in-
pected, pretreatment of HPMCs with PD98059 pre-hibitor of MEK. Our current study evaluated whether
vented the TGF-–stimulated ERK1/2 activation (Fig.TGF- also activates ERK1/2 in HPMC. As shown in
5). Both dipyridamole and DBcAMP abrogated this re-
Figure 3, ERK1/2 pathways were activated beginning
sponse in a dose-dependent manner. At a concentration
within 15 minutes after TGF- was added, peaked at 30 that inhibited collagen gene expression (6 to 17 g/mL;
minutes, and persisted for approximately four hours. To Fig. 1), dipyridamole suppressed the ERK1/2 activation
examine whether this activation of the ERK pathway by TGF-. In contrast, the same concentration of dipyri-
contributed to TGF-–induced collagen gene expression, damole had no effect on TGF-–induced activation of
we evaluated the effect of PD98059 on collagen gene Smad2 (Fig. 6). This implied that the inhibitory effect
expression induced by TGF-. HPMCs were pretreated of dipyridamole on TGF-–induced collagen gene ex-
with various concentrations of PD98059 for one hour and pression in HPMC mainly occurs through modulations
then incubated with TGF- (2.5 ng/mL) for 24 hours of the ERK pathway.
(Fig. 4). As shown, PD98059 suppressed the TGF-–
induced 1(I) mRNA expression in a dose-dependent Interaction of the ERK pathway and the SMAD
manner (Fig. 4). These data indicate that the ERK path- pathway in HPMCs
way is involved in TGF-–mediated collagen gene tran- It has been postulated that the activation of Smad2
scription. by hepatocyte growth factor is downstream of MEK [14].
Although the nature of this interaction is not clear, we
Dipyridamole inhibits activation of ERK1/2, but not performed experiments to evaluate the potential interac-
Smad2, by TGF- tion between these two pathways. HPMC pretreated
To analyze the mechanisms and effect of dipyridamole with PD98059 did not influence the activation of Smad2
on TGF-–mediated collagen gene induction further, the on TGF- treatment (Fig. 7). These observations suggest
effects of dipyridamole on signaling transduction path- that in HPMC, the TGF- signal activates two indepen-
ways downstream to TGF- were examined. As shown, dent pathways: the ERK pathway and the SMAD
pathway.TGF- induced the activation of ERK1/2, and as ex-
Hung et al: Dipyridamole and collagen gene expression 1255
Fig. 5. Evaluation of inhibitory dipyridam-
ole, DBcAMP, and PD98059 on TGF-–
induced ERK1/2 activation in HPMCs. Cell
lysates were immunoblotted as described in
Figure 3. (A) A representative blot from ex-
periments out of four with similar results. (B)
The details of different treatment conditions.
(C) The results of densitometric analysis, ex-
pressed as a ratio between phospho- and non-
phospho-ERK1/2, from four separate experi-
ments. Values in the graph are shown as fold
increase over control. #P  0.05 vs. lane 1;
*P  0.05, relative to lane 2.
Fig. 6. Inhibitory effect of dipyridamole on
TGF-–induced Smad2 activation in HPMC.
HPMCs were pretreated with various concen-
trations of dipyridamole and then were in-
cubated with TGF- for the indicated time
periods. Western blotting was performed as
described in Figure 2. Shown are representa-
tive blots from four separate experiments with
similar results.
DISCUSSION between TGF- and type I collagen gene expression
remains unknown, we evaluated whether the downstreamWe [4] and others [3] have shown that, by inducing
signaling factors of TGF-, SMAD proteins and/or thethe expression of collagen 1(I) and collagen 1(III)
ERK pathway, are modulated by dipyridamole. To ourmRNA in HPMCs, TGF- may be associated with an
knowledge this is the first report investigating the endog-increased risk of PF. Our current study demonstrates that
enous SMAD pathway in the primary culture of HPMCs.dipyridamole inhibits the TGF-–induced expression of
Our study shows that Smad2 and Smad4 are present incollagen 1(I) mRNA mainly through a cAMP-depen-
dent mechanism (Fig. 1). Because the molecular link HPMC (Fig. 2). In response to TGF-, Smad2 is acti-
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Fig. 7. Effect of PD98059 on TGF-–induced
Smad2 activation in HPMCs. HPMCs were
treated with 50 mol/L of PD98059 or control
vehicle for one hour and then incubated with
different concentrations of TGF- for another
30 minutes. Western blotting was performed
as described in Figure 2. Shown are represen-
tative blots from four separate experiments
with similar results.
vated (phosphorylated) in a time-dependent manner. –induced 1(I) collagen mRNA expression (Fig. 1), an
These findings indicate that SMAD proteins participate effect that cannot be fully explained by the complete
in TGF-–induced collagen synthesis and the develop- blockade of the ERK pathway by PD98059 (Fig. 5).
ment of PF. These data implied that dipyridamole inhibited the TGF-
Previous experiments suggest that the Smad2 protein –induced 1(I) collagen mRNA expression through an-
plays a pivotal role in the TGF- signaling pathway [5–7]. other as yet unidentified pathway. A recent study in
However, our data showed that dipyridamole had no NRK fibroblasts demonstrated that one protein, called
effect on TGF-–induced Smad2 activation (Fig. 6). In connective tissue growth factor (CTGF), acts as a down-
contrast, dipyridamole inhibited TGF-–induced activa- stream mediator of TGF-–induced collagen synthesis
tion of the ERK pathway (Fig. 5). To verify this, similar and can be down-regulated by elevated intracellular
experiments were carried out using DBcAMP, which cAMP [16]. The identification of CTGF in TGF-–
inhibited TGF-–induced activation of the ERK pathway treated HPMC and their possible modulation by dipyri-
in a dose-dependent manner (Fig. 5). By using the trypan- damole deserves further study.
blue exclusion method and measuring lactate dehydroge- Given the involvement of the SMAD pathway and
nase (LDH) activity of the supernatant as previously the ERK pathway in TGF- signaling of HPMC, it is
described [4, 13], we found that dipyridamole at a con- intriguing to speculate that potential cross-talk exists
centration of 17g/mL or lower did not result in cytotox- between these two pathways. However, in our current
icity of HPMC (data not shown). Therefore, the inhibi- study, PD98059 failed to prevent TGF-–induced Smad2
tory effects of higher concentrations of dipyridamole on activation in HPMC, and this activation of the Smad2 by
TGF-–induced activation of SMAD proteins were not TGF- was independent of the ERK signaling pathway.
examined. These data imply that the inhibitory effect of These data suggest that in TGF-–treated HPMC, the
dipyridamole on TGF- inducibility of collagen 1(I) SMAD pathway could be a distinct, parallel pathway
gene expression mainly operate through modulations of from the ERK signaling pathway. Further investigation
the ERK pathway rather than of the SMAD proteins.
of these two downstream pathways of TGF- and their
The concept that the ERK pathway may serve as a
possible interactions may elucidate the pleiotropic ef-downstream signaling factor for TGF- and play a role
fects of TGF- in HPMCs.in fibrogenesis is relatively new [15]. Our preliminary
In summary, in HPMCs both the ERK and SMADunpublished finding that dipyridamole and DBcAMP
pathways are involved in the response to TGF-. Theinhibited PDGF-stimulated ERK1/2 activation in HPMC
inhibitory effect of dipyridamole on TGF-–induced col-led to our current study, which demonstrates that the
lagen 1 (I) gene expression may function mainly throughERK pathway in HPMC also is activated by TGF-
modulating the ERK pathway.(Fig. 3). In addition, the blockade of ERK by PD98059
attenuated, but did not completely inhibit, the increase
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